Blood test could revolutionize breast cancer monitoring
NCT ID NCT06807502
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a device called ScreenCell that counts circulating tumor cells (CTCs) in a blood sample from breast cancer patients. Researchers want to see if changes in CTC numbers over time can help track how the cancer is progressing. The study will include 93 women with early-stage or metastatic breast cancer and follow them for up to 36 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to track breast cancer progression and guide treatment decisions.
- What could go wrong
- This is an early observational study, not a treatment trial. The device may not prove reliable enough for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMC Ambroise Paré Hartmann
RECRUITINGNeuilly-sur-Seine, 92200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise during chemo: a new weapon to preserve strength?
- Tailored radiation may spare breast cancer patients from arm swelling
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Could a personal coach at home boost energy for cancer patients?